



# **IMPROVING ADOPTIVE CELL THERAPY**

**MAY 30 & MAY 31, 2024**

**CENTRE DE RECHERCHE DES CORDELIERS**

**PARIS**

Adoptive cell therapy, particularly CAR T-cell therapy, has marked a revolutionary milestone in the treatment of hematological malignancies and is now making strides in the realm of auto-immune diseases. However, for solid tumors, there remains a substantial path ahead.

This congress will delve into the critical aspects of optimizing adoptive cell therapy. The first segment will explore the host conditions for greater efficacy of adoptive cell therapy. Following this, a dedicated session will focus on T-cell engineering, and lastly, we will examine novel targets for CAR T-cell therapy.

The meeting is designed to provide networking between clinicians, scientists from academic and industrial partners in the field of cell therapies.

This event will bring together the foremost experts in immunology, oncology, and cellular therapy.



**MAY 30, 2024**

9 :00 Introduction, Prof Laurence Zitvogel

**I.HOST**

Moderators : Aymeric Silvin, Claudia Pasqualini

**9:15 Yasmine Belkaid, National Institute of Health, USA; Institut Pasteur, France**  
*TBD*

**9:45 Florent Ginhoux, Gustave Roussy, France**  
*Macrophage ontogeny in tumor microenvironment*

**10:15 Jérôme Galon, Centre des Cordeliers, France**  
*TBD*

**10:45 Cécile Alanio, Institut Curie, France**  
*TBD*

**11:15 Julie Heft, Institut Cochin, France**  
*Macrophage subsets and T cell immunity in breast cancer*

**11:45 Camille Bigenwald, Gustave Roussy, France**  
*Host-dependant mechanisms of resistance to CAR T cells*

**BUFFET**

During the lunch break: Paris Saclay Cancer Campus workshop.

**II. TARGETING TUMOR ANTIGENS**

Moderators: Florent Ginhoux, Laurie Menger

**14:00 Robert Majzner, Stanford & Harvard, USA**  
*TBD*

**14:30 Katy Rezvani, MD Anderson Cancer Center, USA**  
*TBD*

**15:00 Sebastian Amigorena, Institut Curie, France**  
*Epigenetic tumor antigens-JET*

**15:30 Alena Gros, Vall d'Hebron Institute of Oncology, Spain**  
*Personalized T-cell therapies for solid cancers*

**BREAK**

**17:00** Short talks (2 best abstracts)

**17:30** Posters teasing (1 min per poster)

**18:00** Poster presentation & cocktail

MAY 31, 2024

**III. T CELL ENGINEERING**

Moderators: Camille Blériot, Camille Bigenwald

**9:00 Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA**

*TBD*

**9:30 Alexander Marson, University of California San Francisco, USA**

*TBD*

**10:00 Laurie Menger, Gustave Roussy, France**

*Advanced T-cell therapy using genome-scale CRISPR screens*

**10:30 Suman Mitra, Lille University Hospital, France**

*Modulating Cytokine Function for Enhanced Immunotherapies*

BREAK

**11:30 Rahul Roychoudhuri, University of Cambridge, England**

*Stemness and maintenance of Treg lineage*

**12:00 Justin Eyquem, University of California San Francisco, USA**

*AAV: efficient genetic engineering of murine T cells*

**12:30 Claire Roddie, University College London, UK**

*AKT inhibitor to enhance polyfunctional CAR-T cell*

**13:00 Luca Gattinoni, Leibniz Institute for Immunotherapy, Germany**

*Boosting T cell-based immunotherapies by mitochondrial transfer*

**13:30 Conclusion, Prof Guido Kroemer**

**Organizing Committee:** Dr Camille Bigenwald, Dr Laurie Menger et Prof Laurence Zitvogel.